论文部分内容阅读
目的:探讨全脑放射治疗后服用厄洛替尼引起的头部皮肤放射治疗回忆反应。方法:对右肺腺癌(T3N2M1)骨转移患者行全脑放疗,DT:40 Gy,20次,4周。放疗结束后即开始服用厄洛替尼150 mg/d。结果:服用厄洛替尼第21 d,开始出现头部皮疹、毛囊炎及局部感染,并逐渐加重,按RTOG急性反应标准评为3级;皮肤严重反应界线与全脑放疗范围一致。停用厄洛替尼,对症处理5 d后明显好转,考虑为厄洛替尼引起的放射治疗回忆反应。结论:放射治疗后服用厄洛替尼有可能引起回忆反应,程度严重时需减量或停药,并积极对症治疗。
Objective: To investigate the response of head skin radiotherapy to erlotinib after whole brain radiotherapy. Methods: Whole brain radiotherapy was performed on patients with right lung adenocarcinoma (T3N2M1) bone metastases, DT: 40 Gy, 20 times for 4 weeks. Erlotinib 150 mg / d started after radiotherapy. Results: Erlotinib on the 21st day began to appear head rash, folliculitis and local infection, and gradually increased, according to RTOG acute reaction standard was rated as 3; severe skin reaction line with the scope of the whole brain radiation. Deactivation of erlotinib, symptomatic treatment after 5 d significantly improved, consider the erlotinib caused by radiotherapy and memory response. Conclusion: Erlotinib after radiotherapy may cause memory reaction, the degree of serious need to reduce or withdrawal, and positive symptomatic treatment.